Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers
Brian A. Gordon, Tyler Blazey, Jon Christensen, et al.
Brain (2019) Vol. 142, Iss. 4, pp. 1063-1076
Open Access | Times Cited: 152

Showing 1-25 of 152 citing articles:

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
Sebastian Palmqvist, Shorena Janelidze, Yakeel T. Quiroz, et al.
JAMA (2020) Vol. 324, Iss. 8, pp. 772-772
Open Access | Times Cited: 953
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 540
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease
Nicolas R. Barthélemy, Yan Li, Nelly Joseph‐Mathurin, et al.
Nature Medicine (2020) Vol. 26, Iss. 3, pp. 398-407
Open Access | Times Cited: 500
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 475
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
Rik van der Kant, Lawrence S.B. Goldstein, Rik Ossenkoppele
Nature reviews. Neuroscience (2019) Vol. 21, Iss. 1, pp. 21-35
Closed Access | Times Cited: 443
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Giovanni B. Frisoni, Daniele Altomare, Dietmar Rudolf Thal, et al.
Nature reviews. Neuroscience (2021) Vol. 23, Iss. 1, pp. 53-66
Open Access | Times Cited: 328
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
Marc Suárez‐Calvet, Thomas K. Karikari, Nicholas J. Ashton, et al.
EMBO Molecular Medicine (2020) Vol. 12, Iss. 12
Open Access | Times Cited: 293
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Stephen Salloway, Martin R. Farlow, Eric McDade, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1187-1196
Open Access | Times Cited: 293
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2381-2387
Open Access | Times Cited: 258
The human connectome in Alzheimer disease — relationship to biomarkers and genetics
Meichen Yu, Olaf Sporns, Andrew J. Saykin
Nature Reviews Neurology (2021) Vol. 17, Iss. 9, pp. 545-563
Open Access | Times Cited: 173
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
Clifford R. Jack, Heather J. Wiste, Hugo Botha, et al.
Brain (2019) Vol. 142, Iss. 10, pp. 3230-3242
Open Access | Times Cited: 158
Early-Onset Alzheimer’s Disease: What Is Missing in Research?
Temitope Ayodele, Ekaterina Rogaeva, Jiji T. Kurup, et al.
Current Neurology and Neuroscience Reports (2021) Vol. 21, Iss. 2
Open Access | Times Cited: 140
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease
Petr Novák, Branislav Kováčech, Stanislav Katina, et al.
Nature Aging (2021) Vol. 1, Iss. 6, pp. 521-534
Closed Access | Times Cited: 123
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
Nicholas J. Ashton, Andréa Lessa Benedet, Tharick A. Pascoal, et al.
EBioMedicine (2022) Vol. 76, pp. 103836-103836
Open Access | Times Cited: 119
Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Daniel W. Sirkis, Luke W. Bonham, Taylor P. Johnson, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 6, pp. 2674-2688
Open Access | Times Cited: 89
Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers
Todd E. Golde
Neurotherapeutics (2022) Vol. 19, Iss. 1, pp. 209-227
Open Access | Times Cited: 82
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Adam L. Boxer, Reisa A. Sperling
Cell (2023) Vol. 186, Iss. 22, pp. 4757-4772
Open Access | Times Cited: 75
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Joseph Therriault, Suzanne E. Schindler, Gemma Salvadó, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 4, pp. 232-244
Closed Access | Times Cited: 53
Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers
Logan Brase, Shih‐Feng You, Ricardo D’Oliveira Albanus, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 48
Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS
Brendan P. Lucey, Haiyan Liu, Cristina D. Toedebusch, et al.
Annals of Neurology (2023) Vol. 94, Iss. 1, pp. 27-40
Open Access | Times Cited: 44
Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer’s disease
Karly Alex Cody, Rebecca E. Langhough, Matthew Zammit, et al.
Brain (2024) Vol. 147, Iss. 6, pp. 2144-2157
Closed Access | Times Cited: 17
Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia
Jorge J. Llibre‐Guerra, María Victoria Fernández, Nelly Joseph‐Mathurin, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 3
Late-onset vs nonmendelian early-onset Alzheimer disease
Christiane Reitz, Ekaterina Rogaeva, Gary W. Beecham
Neurology Genetics (2020) Vol. 6, Iss. 5
Open Access | Times Cited: 128
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease
Kanta Horie, Nicolas R. Barthélemy, Chihiro Sato, et al.
Brain (2020) Vol. 144, Iss. 2, pp. 515-527
Open Access | Times Cited: 120
Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study
Antoinette O’Connor, Thomas K. Karikari, Teresa Poole, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 10, pp. 5967-5976
Open Access | Times Cited: 101
Page 1 - Next Page

Scroll to top